ALK2 (R202I) Recombinant Protein | ALK2 recombinant protein
ALK2 (R202I), Active
Applications
Kinase Assay
Synonyms
ALK2 (R202I); Active; ACVR1; FOP; SKR1; TSRI; ACTRI; ACVR1A; ACVRLK2; ALK2 recombinant protein
Host
Sf9 insect cells
Form/Format
Recombinant protein stored in 50mM Tris-HCl, pH7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol.
Applicable Applications for ALK2 recombinant protein
Kinase Assay
Tag
GST
Species
Human
Preparation and Storage
Store product at -70 degree C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Activity
(Specific Activity: Sample Activity Plot. For specific information on a given lot, see related technical data sheet.)
SDS-Page
(Purity: Sample Purity Data. For specific information on a given lot, see related technical data sheet.)
Related Product Information for ALK2 recombinant protein
Recombinant human ALK2 (R202I)(147-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. The ALK2 gene accession number is NM_001105.
ALK 2 is a receptor serine/threonine kinase that is member of the ALK family and is upstream of signaling pathway involving the SMAD proteins especially SMAD1/5/8. Knockdown of ALK2, but not TGFbetaRI (ALK5), abrogates endoglin-mediated decrease in cell motility of prostate cancer cells and constitutively active ALK2 is sufficient to restore a low-motility phenotype in endoglin deficient cells (1). Therefore, endoglin decreases prostate cancer cell motility through activation of the ALK2-Smad1 pathway. ALK2 is the key gene involved in Fibrodysplasia ossificans progressiva (FOP), a rare autosomal dominant congenital disorder characterized by progressive heterotopic bone formation in muscle tissues (2).
ALK 2 is a receptor serine/threonine kinase that is member of the ALK family and is upstream of signaling pathway involving the SMAD proteins especially SMAD1/5/8. Knockdown of ALK2, but not TGFbetaRI (ALK5), abrogates endoglin-mediated decrease in cell motility of prostate cancer cells and constitutively active ALK2 is sufficient to restore a low-motility phenotype in endoglin deficient cells (1). Therefore, endoglin decreases prostate cancer cell motility through activation of the ALK2-Smad1 pathway. ALK2 is the key gene involved in Fibrodysplasia ossificans progressiva (FOP), a rare autosomal dominant congenital disorder characterized by progressive heterotopic bone formation in muscle tissues (2).
Product Categories/Family for ALK2 recombinant protein
References
1. Craft, C.S. et al: Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene. 2007 Nov 8;26(51):7240-50.
2. Shore, E. M. et al: A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nature Genet. 38: 525-527, 2006.
2. Shore, E. M. et al: A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nature Genet. 38: 525-527, 2006.
NCBI and Uniprot Product Information
NCBI Accession #
NCBI GenBank Nucleotide #
Molecular Weight
67kDa
Protein Family
